tbuckley/cabot-search huggingface dataset:
Abstract 12543: Smartphone Delivered Cardiac Rehab for Heart Failure Management: A Feasibility Study
Authors: Harshvardhan Vathsangam, Shuo Qiao, Julie Berkley, Adelanwa Adesanya, Gaurav Sukhatme, Luanda Grazette, Michael Fong
Journal: Circulation (2015)

Background: Congestive heart failure (CHF) is the leading cause of hospitalization. Exercise training and self-care counseling through cardiac rehab (CR) benefits CHF patients by increasing exercise tolerance, improving clinical symptoms and reducing risk of future clinical events. However, CR programs are severely underutilized due to high insurance co-pays and issues with access. Remote CR programs delivered through patients’ smartphones show promise in addressing this gap. We studied the feasibility of utilizing a mobile application to implement a home-based cardiac rehab program for CHF patients. Methods: Ten consecutive ambulatory patients with a prior history of CHF and an Android smartphone downloaded and received training for the cardiac rehab smartphone application. The application engaged the patient to complete daily tasks at home. Data were wirelessly collected for 14 days. Metrics evaluated included passively collected activity (minutes), compliance to weight &amp; blood pressure tracking and viewing of educational tasks. Patient on-boarding time was also tracked. Results: A broad range of patients were included in the study (Table 1); 20% were inotrope dependent. On-boarding took an average of 15 minutes. Table 1 summarizes results. Participants met minimum recommended daily activity (30 minutes) an average of 8±5 days in the 14 day period. Four participants entered vital sign values only in the office, possibility indicating lack of equipment at home. Conclusion: A smartphone-based remote cardiac rehab is feasible and useful in a fairly ill population. Minimum daily activity can be achieved and education content can be effectively delivered. However, results indicate the need to engage participants more to complete educational tasks. Participants need to be provided scales and blood pressure cuffs to track vital signs at home. Further study is warranted to assess the effect of this application on functional capacity and symptoms.
カベオリン‐キャビン複合体の成分で,心筋細胞でカベオラ形態学を調節する筋肉限定コイルドコイル蛋白質MURC
Authors: Naito Daisuke, Amano Katsuya, Ogata Takehiro, Taniguchi Takuya, Nakanishi Naohiko, Miyagawa Kotaro, Hayashi Yukiko, Morimoto Tatsuya, Ueyama Tomomi, Matsubara Hiroaki
Journal: Circulation (2011)
Phase I trial of the triplet veliparib + VX-970 + cisplatin in patients with advanced solid tumors.
Authors: Geraldine Helen O'Sullivan Coyne, Shivaani Kummar, Robert S. Meehan, Lamin Juwara, Richard Piekarz, Elad Sharon, Howard Streicher, Barbara A. Conley, Naoko Takebe, Lyndsay Harris, Austin Doyle, Mary Flanagan Quinn, Larry Rubinstein, Deborah Wilsker, Robert J. Kinders, Ralph E. Parchment, Elliot B Levy, James H. Doroshow, Alice P. Chen
Journal: Journal of Clinical Oncology (2017)

TPS2609 Background: The DNA damage response (DDR) pathway is a key element of cellular integrity. Platinum compounds form covalent bonds with purine bases causing DNA cross-links that stall replication forks halting transcription. Poly (ADP-ribose)polymerase-1 (PARP-1) plays a pivotal role in DDR and base-excision repair. Ataxia-telangiectasia-related (ATR) protein kinase is also central to DDR and homologous recombination, activating a series of phosphorylation cascades culminating in cell cycle arrest to allow time for DNA repair. Veliparib (ABT-888) is a PARP 1/2 inhibitor (PARPi) with clinical evidence of antitumor activity in combination with cisplatin in BRCA mutation carriers (Rodler et al, Cancer Res. 2011). VX-970 is a potent ATR inhibitor, with antitumor activity across a range of cell lines in combination with DNA damaging agents, including cisplatin (Huntoon et al, Cancer Res. 2013). In this trial, we will evaluate whether the combination of veliparib + VX-970 impairs DNA repair, inducing a “BRCA null”-like phenotype leading to potentiation of the antitumor activity of cisplatin. Methods: Open label phase I trial of the veliparib+VX-970+cisplatin combination, following a 3+3 design, with dose limiting toxicities defined during cycle 1. Estimated enrollment: 24 patients (pts); Dana Farber and MD Anderson planned as additional sites. Drug administration over a 21-day cycle: VX- intravenously (IV) on Days 2 and 9; Veliparib orally twice daily (q12 hours ± 1 hour) Days 1-3 and 8-10; cisplatin 40 mg/m 2 IV Day 1 (with Day 8 added from DL3 onwards). Pts must be ≥ 18 years of age; have histologically confirmed solid tumors that have progressed on standard of care therapy known to prolong survival or without known standard, ECOG PS ≤2, and life expectancy ≥3 months. Pts with treated brain metastasis with stable disease ≥4 weeks without requiring steroids or anti-seizure medication are eligible. Exclusion criteria include a prolonged QTc interval, and sensory/motor neuropathy ≥grade 2 by CTCAE v.4. At this time, cohort 3 has enrolled 1 of 3 planned pts. Assessment of DDR and apoptosis biomarkers at the maximally tolerated dose using a validated and quantitative immunofluorescence assay is planned. Clinical trial information: NCT02723864.
<i>Bifidobacterium animalis subspecies lactis</i>modulates the local immune response and glucose uptake in the small intestine of juvenile pigs infected with the parasitic nematode<i>Ascaris suum</i>
Authors: Gloria Solano-Aguilar, Terez Shea-Donohue, Kathleen B. Madden, Alejandro Quinoñes, Ethiopia Beshah, Sukla Lakshman, Yue Xie, Harry Dawson, Joseph F. Urban
Journal: Gut Microbes (2018)

An evaluation of a localized intestinal allergic type-2 response concomitant with consumption of probiotic bacteria is not well documented. This study investigated the effect of feeding probiotic Bifidobacterium animalis subspecies lactis (Bb12) or a placebo in weaned pigs that were also inoculated with Ascaris suum (A. suum) eggs to induce a strong Th2-dependent allergic type 2 immune response. Sections of jejunal mucosa were mounted in Ussing chambers to determine changes in permeability and glucose absorption, intestine and liver samples were collected for analysis of type-2 related gene expression, jejunum examined histologically, and sera and intestinal fluid were assayed for parasite antigen specific antibody. The prototypical parasite-induced secretory response to histamine and reduced absorption of glucose in the jejunum were attenuated by feeding Bb12 without a change in mucosal resistance. Parasite antigen-specific IgA response in the serum and IgG1 and IgG2 response in the ileal fluid were significantly increased in A. suum-infected pigs treated with Bb12 compared to infected pigs given the placebo. Ascaris suum-induced eosinophilia in the small intestinal mucosa was inhibited by Bb12 treatment without affecting the normal expulsion of A. suum 4th stage larvae (L4) or the morphometry of the intestine. Expression of genes associated with Th1/Th2 cells, Treg cells, mast cells, and physiological function in the intestine were modulated in A. suum infected-pigs treated with Bb12. These results suggested that Bb12 can alter local immune responses and improve intestinal function during a nematode infection by reducing components of a strong allergenic type-2 response in the pig without compromising normal parasite expulsion.
Annals Story Slam - The Little Things
Authors: Neena Mohan
Journal: Annals of Internal Medicine (2018)

Web Exclusives17 July 2018Annals Story Slam - The Little ThingsFREENeena Mohan, MDNeena Mohan, MDCooper University Hospital, Camden, New Jersey (N.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W18-0022 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - The Little Things "The Little Things," by Neena Mohan (Duration 5:06)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Cooper University Hospital, Camden, New Jersey (N.M.)Corresponding Author: Neena Mohan, MD; e-mail, [email protected]com. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 17 July 2018Volume 169, Issue 2Page: SS1 ePublished: 17 July 2018 Issue Published: 17 July 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.Loading ...
Focused ultrasound combined with microbubble-mediated intranasal delivery of gold nanoclusters to the brain
Authors: Dezhuang Ye, Xiaohui Zhang, Yimei Yue, Ramesh Raliya, Pratim Biswas, Sara Taylor, Yuan-chuan Tai, Joshua B. Rubin, Yongjian Liu, Hong Chen
Journal: Journal of Controlled Release (2018)
At “Crisis Pregnancy Centers,” Critics Say, Ideology Trumps Evidence
Authors: Rita Rubin
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions
Authors: Florian H. Heidel, Haifa-Kathrin Al-Ali, Carsten Hirt, Dietrich Kämpfe, Kathleen Jentsch-Ullrich, Christian Junghanss, Ralf Nowak, Andreas Schwarzer, Claudia Spohn, Vladan Vucinic, Andreas Hochhaus, Thoralf Lange
Journal: Leukemia (2018)
A JUST DECISION.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Primum Non Nocere: Refocusing Our Attention on Severe Hypoglycemia Prevention
Authors: Anna R. Kahkoska, John B. Buse
Journal: Diabetes Care (2018)

Severe hypoglycemia, defined as low blood glucose requiring assistance for recovery, is arguably the most dangerous complication of type 1 diabetes as it can result in permanent cognitive impairment, seizure, coma, accidents, and death (1,2). Since the Diabetes Control and Complications Trial (DCCT) demonstrated that intensive intervention to normalize glucose prevents long-term complications but at the price of a threefold increase in the rate of severe hypoglycemia (3), hypoglycemia has been recognized as the major limitation to achieving tight glycemic control. Severe hypoglycemia remains prevalent among adults with type 1 diabetes, ranging from ∼1.4% per year in the DCCT/EDIC (Epidemiology of Diabetes Interventions and Complications) follow-up cohort (4) to ∼8% in the T1D Exchange clinic registry (5).

One the greatest risk factors for severe hypoglycemia is impaired awareness of hypoglycemia (6), which increases risk up to sixfold (7,8). Hypoglycemia unawareness results from deficient counterregulation (9), where falling glucose fails to activate the autonomic nervous system to produce neuroglycopenic symptoms that normally help patients identify and respond to episodes (i.e., sweating, palpitations, hunger) (2). An estimated 20–25% of adults with type 1 diabetes have impaired hypoglycemia awareness (8), which increases to more than 50% after 25 years of disease duration (10).

Screening for hypoglycemia unawareness to identify patients at increased risk of severe hypoglycemic events should be part of routine diabetes care. Self-identified impairment in awareness tends to agree with clinical evaluation (11). Therefore, hypoglycemia unawareness can be easily and effectively screened using multiple, self-administered methods (11). These range from single questions (i.e., “Do you know when your hypos are coming?” [7] and “Can you feel when you are low?” [12]) to longer assessments characterizing hypoglycemia exposure and the glycemic threshold for symptomatic response, as in the 8-item Clarke questionnaire (11 …
Oxygen‐dependent flow of sickle trait blood as an <i>in vitro</i> therapeutic benchmark for sickle cell disease treatments
Authors: Xinran Lu, Anwesha Chaudhury, John M. Higgins, David K. Wood
Journal: American Journal of Hematology (2018)

Abstract Although homozygous sickle cell disease is often clinically severe, the corresponding heterozygous state, sickle cell trait, is almost completely benign despite the fact that there is only a modest difference in sickle hemoglobin levels between the two conditions. In both conditions, hypoxia can lead to polymerization of sickle hemoglobin, changes in red cell mechanical properties, and impaired blood flow. Here, we test the hypothesis that differences in the oxygen‐dependent rheological properties in the two conditions might help explain the difference in clinical phenotypes. We use a microfluidic platform that permits quantification of blood rheology under defined oxygen conditions in physiologically sized microchannels and under physiologic shear rates. We find that, even with its lower sickle hemoglobin concentration, sickle trait blood apparent viscosity increases with decreasing oxygen tension and may stop flowing under completely anoxic conditions, though far less readily than the homozygous condition. Sickle cell trait blood flow becomes impaired at significantly lower oxygen tension than sickle cell disease. We also demonstrate how sickle cell trait can serve as a benchmark for sickle cell disease therapies. We characterize the rheological effects of exchange transfusion therapy by mixing sickle blood with nonsickle blood and quantifying the transfusion targets for sickle hemoglobin composition below which the rheological response resembles sickle trait. These studies quantify the differences in blood flow phenotypes of sickle cell disease and sickle cell trait, and they provide a potentially powerful new benchmark for evaluating putative therapies in vitro .
Role of IL-35 in sublingual allergen immunotherapy
Authors: Mohamed H. Shamji, Janice A. Layhadi, Daniela Achkova, Lubna Kouser, Alan Perera-Webb, Natália C. Couto-Francisco, Rebecca V. Parkin, Tomokazu Matsuoka, Guy Scadding, Philip G. Ashton-Rickardt, Stephen R. Durham
Journal: Journal of Allergy and Clinical Immunology (2018)

BackgroundGrass pollen–specific immunotherapy involves immunomodulation of allergen-specific TH2 responses and induction of IL-10+ and/or TGF-β+CD4+CD25+ regulatory T cells (induced Treg cells). IL-35+CD4+CD25+ forkhead box protein 3–negative T (IL-35–inducible regulatory T [iTR35]) cells have been reported as a novel subset of induced Treg cells with modulatory characteristics.ObjectiveWe sought to investigate mechanisms underlying the induction and maintenance of immunologic tolerance induced by IL-35 and iTR35 cells.MethodsThe biological effects of IL-35 were assessed on group 2 innate lymphoid cells (ILC2s); dendritic cells primed with thymic stromal lymphopoietin, IL-25, and IL-33; and B and TH2 cells by using flow cytometry and quantitative RT-PCR. Grass pollen–driven TH2 cell proliferation and cytokine production were measured by using tritiated thymidine and Luminex MagPix, respectively. iTR35 cells were quantified in patients with grass pollen allergy (seasonal allergic rhinitis [SAR] group, n = 16), sublingual immunotherapy (SLIT)–treated patients (SLIT group, n = 16), and nonatopic control subjects (NACs; NAC group, n = 16).ResultsThe SAR group had increased proportions of ILC2s (P = .002) and IL-5+ cells (P = .042), IL-13+ cells (P = .042), and IL-5+IL-13+ ILC2s (P = .003) compared with NACs. IL-35 inhibited IL-5 and IL-13 production by ILC2s in the presence of IL-25 or IL-33 (P = .031) and allergen-driven TH2 cytokines by effector T cells. IL-35 inhibited CD40 ligand–, IL-4–, and IL-21–mediated IgE production by B cells (P = .015), allergen-driven T-cell proliferation (P = .001), and TH2 cytokine production mediated by primed dendritic cells. iTR35 cells suppressed TH2 cell proliferation and cytokine production. In addition, allergen-driven IL-35 levels and iTR35 cell counts were increased in patients receiving SLIT (all, P < .001) and NACs (all, P < .001) compared with patients with SAR.ConclusionIL-35 and iTR35 cells are potential novel immune regulators induced by SLIT. The clinical relevance of SLIT can be underscored by restoration of protective iTR35 cells.Graphical abstract
Tracking key virulence loci encoding aerobactin and salmochelin siderophore synthesis in Klebsiella pneumoniae
Authors: Margaret M. C. Lam, Kelly L. Wyres, Louise M. Judd, Ryan R. Wick, Adam Jenney, Sylvain Brisse, Kathryn E. Holt
Journal: Genome Medicine (2018)

Klebsiella pneumoniae is a recognised agent of multidrug-resistant (MDR) healthcare-associated infections; however, individual strains vary in their virulence potential due to the presence of mobile accessory genes. In particular, gene clusters encoding the biosynthesis of siderophores aerobactin (iuc) and salmochelin (iro) are associated with invasive disease and are common amongst hypervirulent K. pneumoniae clones that cause severe community-associated infections such as liver abscess and pneumonia. Concerningly, iuc has also been reported in MDR strains in the hospital setting, where it was associated with increased mortality, highlighting the need to understand, detect and track the mobility of these virulence loci in the K. pneumoniae population.
Surgeon who failed to tell patient of error is struck off
Authors: Clare Dyer
Journal: BMJ (2018)

A former consultant orthopaedic surgeon has been struck off the UK medical register for trying to cover up a serious surgical error.

Edward Jago operated on the wrong part of a patient’s knee but failed to tell the patient when he discovered his mistake, a medical practitioners’ tribunal found. He made a false note in the patient’s records and continued to deny his error in three interviews with his employers, St Helens and Knowsley NHS Trust.

The patient sustained a twisting injury to his left knee when playing football aged 15. He had four operations on the knee between …
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Authors: Daniel J Wallace, Richard A Furie, Yoshiya Tanaka, Kenneth C Kalunian, Marta Mosca, Michelle A Petri, Thomas Dörner, Mario H Cardiel, Ian N Bruce, Elisa Gomez, Tara Carmack, Amy M DeLozier, Jonathan M Janes, Matthew D Linnik, Stephanie de Bono, Maria E Silk, Robert W Hoffman
Journal: The Lancet (2018)
Recent developments in topoisomerase-targeted cancer chemotherapy
Authors: KirkE. Hevener, Tatsiana A. Verstak, Katie E. Lutat, Daniel L. Riggsbee, Jeremiah W. Mooney
Journal: Acta Pharmaceutica Sinica B (2018)

The DNA topoisomerase enzymes are essential to cell function and are found ubiquitously in all domains of life. The various topoisomerase enzymes perform a wide range of functions related to the maintenance of DNA topology during DNA replication, and transcription are the targets of a wide range of antimicrobial and cancer chemotherapeutic agents. Natural product-derived agents, such as the camptothecin, anthracycline, and podophyllotoxin drugs, have seen broad use in the treatment of many types of cancer. Selective targeting of the topoisomerase enzymes for cancer treatment continues to be a highly active area of basic and clinical research. The focus of this review will be to summarize the current state of the art with respect to clinically used topoisomerase inhibitors for targeted cancer treatment and to discuss the pharmacology and chemistry of promising new topoisomerase inhibitors in clinical and pre-clinical development.
Abnormal neutrophil traps and impaired efferocytosis contribute to liver injury and sepsis severity after binge alcohol use
Authors: Terence Ndonyi Bukong, Yeonhee Cho, Arvin Iracheta-Vellve, Banishree Saha, Patrick Lowe, Adeyinka Adejumo, Istvan Furi, Aditya Ambade, Benedek Gyongyosi, Donna Catalano, Karen Kodys, Gyongyi Szabo
Journal: Journal of Hepatology (2018)